AZD8931 diFuMaric acid

SKU: orb1298662

Description

AZD8931 is a potent, ATP-competitive inhibitor of EGFR, ErbB2, and ErbB3 with IC50 values of 4, 3, and 4 nM, respectively. It is used in cancer research to study signaling pathways and has demonstrated antitumor activity in both cellular assays and in vivo xenograft models.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1196531-39-1
• MW: 706.1
• Purity: 99.92% (May vary between batches)
• Formula: C₃₁H₃₃ClFN₅O₁₁
• SMILES: OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC
• Target: EGFR
• Solubility: DMSO:30 mg/mL (42.49 mM)

Bioactivity

• Target IC50:
  EGFR:4 nM |ErbB2:3 nM |ERB3:4 nM
• In Vivo:
  AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth.
  Read more...
• Animal Research:
  Two IBC cell lines SUM149 and FC-IBC-02 。Cell growth and apoptotic cell death were examined in vitro. For the in vivo tumor growth studies, IBC cells were orthotopically transplanted into the mammary fat pads of immunodeficient mice. AZD8931 was given by daily oral gavage at doses of 25 mg/kg, 5 days/week for 4 weeks. Paclitaxel was subcutaneously injected twice weekly.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ErbB3, EGFR, ErbB2, AZD8931 diFuMaric acid, AZD-8931 diFuMaric acid

Compound Identifiers

PubChem CID

44470103